Evidence map›Paper›PMID 26683227›Full record

ArticleOncotarget2016

SHIP represses lung inflammation and inhibits mammary tumor metastasis in BALB/c mice.

Melisa J Hamilton, Elizabeth C Halvorsen, Nancy E LePard, Momir Bosiljcic, Victor W Ho, Vivian Lam, Judit Banáth, Kevin L Bennewith, Gerald Krystal

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. IL-33 increases ST2Oncoimmunology
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Melisa J HamiltonDepartment of Integrative Oncology, British Columbia Cancer Agency Research Centre, Vancouver, BC, Canada.
Elizabeth C HalvorsenDepartment of Integrative Oncology, British Columbia Cancer Agency Research Centre, Vancouver, BC, Canada.
Nancy E LePardDepartment of Integrative Oncology, British Columbia Cancer Agency Research Centre, Vancouver, BC, Canada.
Momir BosiljcicDepartment of Integrative Oncology, British Columbia Cancer Agency Research Centre, Vancouver, BC, Canada.
Victor W HoTerry Fox Laboratory, British Columbia Cancer Agency Research Centre, Vancouver, BC, Canada.
Vivian LamTerry Fox Laboratory, British Columbia Cancer Agency Research Centre, Vancouver, BC, Canada.
Judit BanáthDepartment of Integrative Oncology, British Columbia Cancer Agency Research Centre, Vancouver, BC, Canada.
Kevin L BennewithDepartment of Integrative Oncology, British Columbia Cancer Agency Research Centre, Vancouver, BC, Canada.
Gerald KrystalTerry Fox Laboratory, British Columbia Cancer Agency Research Centre, Vancouver, BC, Canada.
BC Cancer Agency · CA

Funding

Canadian Institutes of Health Research MOP-126138
6 · The paper itself

Abstract

SH2-containing-inositol-5'-phosphatase (SHIP) is a negative regulator of the phosphatidylinositol-3-kinase pathway in hematopoietic cells and limits the development of leukemias and lymphomas. The potential role of SHIP in solid tumor development and metastasis remains unknown. While SHIP restricts the aberrant development of myeloid cells in C57BL/6 mice, there are conflicting reports regarding the effect of SHIP deletion in BALB/c mice with important consequences for determining the influence of SHIP in different model tumor systems. We generated SHIP-/- BALB/c mice and challenged them with syngeneic non-metastatic 67NR or metastatic 4T1 mammary tumors. We demonstrate that SHIP restricts the development, alternative-activation, and immunosuppressive function of myeloid cells in tumor-free and tumor-bearing BALB/c mice. Tumor-free SHIP-/- BALB/c mice exhibited pulmonary inflammation, myeloid hyperplasia, and M2-polarized macrophages and this phenotype was greatly exacerbated by 4T1, but not 67NR, tumors. 4T1-bearing SHIP-/- mice rapidly lost weight and died from necrohemorrhagic inflammatory pulmonary disease, characterized by massive infiltration of pulmonary macrophages and myeloid-derived suppressor cells that were more M2-polarized and immunosuppressive than wild-type cells. Importantly, while SHIP loss did not affect primary tumor growth, 4T1-bearing SHIP-/- mice had 7.5-fold more metastatic tumor cells in their lungs than wild-type mice, consistent with the influence of immunosuppressive myeloid cells on metastatic growth. Our findings identify the hematopoietic cell-restricted protein SHIP as an intriguing target to influence the development of solid tumor metastases, and support development of SHIP agonists to prevent the accumulation of immunosuppressive myeloid cells and tumor metastases in the lungs to improve treatment of metastatic breast cancer.

Indexed as

AnimalsApoptosisBlotting, WesternCell ProliferationFemaleHumansImmunoenzyme TechniquesInositol Polyphosphate 5-PhosphatasesLung NeoplasmsMacrophagesMammary Neoplasms, ExperimentalMiceMice, Inbred BALB CMice, Inbred C3HMice, Inbred C57BLMice, KnockoutInositol Polyphosphate 5-PhosphatasesPhosphoric Monoester Hydrolases4T1BALB/cmetastasismyeloid cellsSHIP

Identifiers

PMID26683227
PMCPMC4826161
OpenAlexW2262125976

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.